Fractalkine (CX3CL1): a biomarker reflecting symptomatic severity in patients with knee osteoarthritis.

Abstract

BACKGROUND:

Elevated serum and synovial fluid (SF) fractalkine (CX3CL1) levels have been detected in patients with knee osteoarthritis (OA). The current study was carried out to investigate the association between serum and SF fractalkine levels with symptomatic severity in patients with knee OA.

METHOD:

One hundred ninety-three patients with OA and 182 healthy controls were enrolled in this study. The symptomatic severity was assessed by the Western Ontario McMaster University Osteoarthritis scores.

RESULTS:

Fractalkine levels in SF and serum were both positively associated with self-reported greater pain and physical disability.

CONCLUSIONS:

Fractalkine in SF and serum may serve as a biomarker for reflecting symptomatic severity. Therapeutic interventions that target fractalkine signaling pathways to delay OA-related symptoms deserve further study.

• Authors: Li Wei Huo, Yong Liang Ye, Guang Wei Wang, Yong Guang Ye
• Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research (J Investig Med) Vol. 63 Issue 4 Pg. 626-31 (Apr 2015) ISSN: 1708-8267 [Electronic] England
• PMID: 25692263 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• CX3CL1 protein, human
• Chemokine CX3CL1

Topics

• Aged
• Biomarkers (blood)
• Case-Control Studies
• Chemokine CX3CL1 (blood)
• Female
• Humans
• Male
• Middle Aged
• Osteoarthritis, Knee (blood, diagnosis)
• Severity of Illness Index
• Synovial Fluid (metabolism)